Greater effort should be directed at detecting and aggressively treating prostate cancer metastasis earlier, an approach made possible with the advent of highly sensitive and specific molecular imaging techniques and potent anticancer agents.
Longer prostate cancer-specific survival seen for specific subgroups, including those with the CYP1A2 AA genotype
Pelvic lymph node metastases visualized on PSMA PET/CT prior to prostate cancer surgery independently predicts an increased risk for biochemical disease progression, a study found.
Sleep apnea and related hypoxia more severe in obstructive sleep apnea patients with cancer compared with those without cancer
Treatment with 177lutetium-PSMA-617 (177Lu-PSMA) is safe and effective in patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously received 223radium (223Ra), according to study findings presented at the European Society for Medical Oncology’s 2022 Congress (ESMO 2022) in Paris, France. In a study of 133 patients who participated in the RALU trial, Kambiz Rahbar,…
Study findings suggest that PSMA PET results may alter treatment decisions in high-risk prostate cancer.
Investigators characterized practice patterns in the first-line treatment of nonmetastatic castration-resistant prostate cancer using real-world data.
Phase 3 results appear to support intensification of ADT in patients with biochemically recurrent prostate cancer.
Increase in survival of men with mCSPC during 2015-2019 coincides with the use of docetaxel and novel hormonal therapies for this disease state.
Investigators estimated disease trajectory and outcomes up to 30 years after the start of prostate cancer active surveillance.